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IntoducObjectivestionzz
γ-Aminobutyric Acid Inhibits Synergistic Interleukin-6 
Release and Increases Intracellular Cytokine Content in C6 
Astrocytoma Cells In Vitro
Daniella Sandoval1, Becky M. Hess1,  Bryan L. Spangelo11
Department of Chemistry, University of Nevada, Las Vegas, NV
Alzheimer’s disease (AD) is a neurodegenerative disorder that is 
characterized by memory loss and is the most common cause of 
dementia. It is has been hypothesized that pro-inflammatory cytokines 
induce the inflammation that is believed to be the cause of the neuronal 
death that is associated with AD. γ-aminobutyric acid (GABA) is a major 
inhibitory neurotransmitter in the Central Nervous System possessing 
membrane hyperpolarization or depolarization activities. A decline in 
GABA may enhance cytokine release in Alzheimer’s disease resulting in 
neuroinflammation.  Therefore, we investigated the GABA-mediated 
suppression of the synergistic release of interleukin-6 (IL-6) induced by 
interleukin 1- (IL-1) and tumor necrosis factor  (TNF-). In this study 
our aim was to determine the sub-cellular location of the accumulated IL-
6 within Rat C6 astrocytoma cells and to determine the receptor through 
which GABA is acting to cause the intracellular accumulation of IL-6. We 
hypothesize that the accumulation occurs within the Golgi apparatus and 
that the GABAB receptor is acted upon to inhibit the release of 
IL-6.
Effect of  GABA or brefeldin A (BFA) on IL-1 and TNF- (TI) mediated 
synergistic expression of IL-6. Cells were pre-treated with GABA (1 mM) or BFA 
(0.5 mg/mL) for 1 h followed by co-treatment with IL-1 (50 ng/mL) and TNF-  (100 
ng/mL) for 24 h.  Cells were visualized by fluorescent microscopy. IL-6 was 
visualized using a monoclonal mouse anti-rat IL-6 antibody (Santa Cruz).  Golgi was 
visualized using a polyclonal rabbit ant-rat TGN-38 antibody.  Control = untreated; TI 
= TNF-  /IL-1 co-treatment; GTI = GABA/ TNF-  /IL-1 co-treatment; BTI = BFA/ 
TNF-  /IL-1 co-treatment. Data are representative of 3 independent trials.
Effect of GABA and brefeldin-A (BFA) on cytokine-driven 
alterations of intracellular and extracellular IL-6 accumulations 
in rat C6 astrocytoma cells in vitro. Cells were pre-treated with 
either GABA (1 mM) or BFA (0.5. mg/ml) for 1 h.  Cells were 
subsequently treated for 24 h with TNF-  (100 ng/mL), IL-1 (50 
ng/mL), or both cytokines (i.e., TI).  GABA or BFA were also 
included with TI for 24 h as indicated. Supernatant was removed 
and cellular lysates generated using M-PER (Pierce).  ELISA was 
used to determine medium and lysate IL-6 concentrations (Pierce).  
The data are presented as mean + SEM of triplicate observations 







• Rat C6 astrocytoma cell line was used as model system
• Immonofluorescence microscopy
• Used to determine subcellular location of accumulated IL-6
• Enzyme-Linked Immunosorbent Assay (ELISA)
•Used to determine concentration of  IL-6  in C6 Rat Astrocytoma
supernatant  and lysate
Effect of GABA, TI, and GABAA receptor antagonist ,or 
GABAB receptor antagonist on extracellular levels of IL-6 
(pg/mL) in rat C6 astrocytoma cells in vitro. Cells were pre-
treated with the GABAA antagonist phaclofen (100 μM) or the 
GABAB antagonist bicuculline (20 μM) for 1 h followed by co-
exposure to either antagonist plus GABA (1mM) for 1h. 
Supernatants were collected following a 24 h treatment of cells 
with antagonist plus GABA in the presence of TI. ELISA was used 
to determine supernatant IL-6 concentrations (Pierce).  The data 
are presented as mean + SEM of quadruplicate observations from 
a single representative experiment repeated three times.
Effect of GABA and TNF- plus IL-1 (TI) on extracellular levels 
of IL-6 in rat C6 astrocytoma cells in vitro. Cells were pre-treated 
with 0.1-1.0 mM GABA for 1 h. Cells were subsequently treated for 24 
hours simultaneously with GABA and TI for 24 h ELISA was used to 
determine extracellular IL-6 concentrations (Pierce). The data are 
presented as a + SEM of triplicate observations from a single 
representative experiment repeated four times.
Effect of GABA, TI, and GABAA receptor agonist, or GABAB receptor agonist 
on extracellular levels of IL-6 (pg/mL) in rat C6 astrocytoma cells in vitro. 
Cells were pre-treated with GABA (1mM), GABAA  receptor agonist muscimol (100 
μM ) or the GABAB receptor agonist baclofen (100 μM) for 1 h. Supernatants were 
collected following a 24 hour treatment with GABA or agonist in the presence of TI. 
ELISA was used to determine supernatant IL-6 concentrations (Pierce).  The data 
are presented as mean + SEM of quadruplicate observations from a single 
representative experiment repeated two times.
• Immunofluorescence microscopy 
• Accumulation of IL-6 was disbursed throughout the cell with little or 
no accumulation within the Golgi apparatus. 
• Cells treated with GABA and TI showed the greatest intracellular 
accumulation of IL-6 
•Enzyme-Linked Immunosorbent Assay
• GABA dose-dependently suppressed the TI mediated release of 
IL-6
• GABA  causes an intracellular accumulation of IL-6
• Neither phaclofen nor bicuculline completely reversed the GABA 
suppression of the TI-mediated IL-6 release. 
• Baclofen and muscimol yielded similar levels of suppression of IL-
6 release
We conclude that the intracellular accumulation of IL-6 is not located solely 
in the Golgi apparatus and in fact the diffuse distribution leads us to 
believe that GABA is acting at the cellular membrane to inhibit the release 
of IL-6. The immunofluorescence microscopy confirms an overall increase 
in the intracellular content of IL-6 in GTI treated cells as also shown by 
ELISA. When treated with GABA receptor antagonists or agonists the 
levels of associated IL-6 release were very similar, leading us to further 
conclude that GABA is not selectively acting on the GABAA receptor or the 
GABAB receptor alone, but instead acts on both receptors to suppress the 
TI mediated synergistic release of IL-6.
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